[CAS NO. 1351522-04-7] AC710
PRODUCTS SPECIFICATIONS [1351522-04-7]
DESCRIPTION [1351522-04-7]
Overview
| MDL | MFCD25976599 |
|---|---|
| Molecular Weight | 562.70 |
| Molecular Formula | C31H42N6O4 |
| SMILES | O=C(C1=NC=C(OC2CC(C)(C)N(CC)C(C)(C)C2)C=C1)NC3=CC=C(NC(NC4=NOC(C(C)(C)C)=C4)=O)C=C3 |
Summary
IC50 & Target
|
PDGFRα 1.3 nM (Kd) |
PDGFRβ 1 nM (Kd) |
c-Kit 1 nM (Kd) |
FLT3 0.6 nM (Kd) |
CSF1R 1.57 nM (Kd) |
In Vivo
At 0.3 mg/kg of AC710, tumor growth is temporally inhibited, and growth resumes quickly thereafter. At 3 and 30 mg/kg of AC710, tumors regress completely, and the tumor volume stays suppressed for an extended period after dosing is halted. No body weight loss is observed in animals treated with AC710 at all doses, indicating that it is well tolerated in mice at efficacious doses. AC710 exhibits a significant impact on disease in a dose-dependent fashion in a mouse collagen-induced arthritis (CIA) model, at a dose as low as 3 mg/ kg for 15 days (day 0-14). At 10 and 30 mg/kg, AC710 demonstrates equivalent or slightly better efficacy in reducing the joint swelling and inflammation than dexomethasone administered at a safe dose. AC710 is well tolerated at the tested doses [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 14 mg/mL ( 24.88 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7771 mL | 8.8857 mL | 17.7715 mL |
| 5 mM | 0.3554 mL | 1.7771 mL | 3.5543 mL |
| 10 mM | 0.1777 mL | 0.8886 mL | 1.7771 mL |